Xenetic Biosciences, Inc. Stock

$3.66

0.81% day before yesterday

Nasdaq, Jul 18, 10:00 pm CET

ISIN

US9840152063

Symbol

XBIO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Xenetic Biosciences, Inc. Stock price

$3.66

-11.94 76.54% 5Y

Nasdaq, Closing price Fri, Jul 18 2025

-0.03 0.81%

ISIN

US9840152063

Symbol

XBIO

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$5.6m

Enterprise Value

$480.0k

Net debt

positive

Cash

$5.2m

Shares outstanding

1.5m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

2.2 | 2.0

EV/Sales

0.2 | 0.2

EV/FCF

negative

P/B

1.1

Financial Health

Equity Ratio

87.0%

Return on Equity

-65.9%

ROCE

-75.8%

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

$2.6m | $2.8m

EBITDA

- | $-5.6m

EBIT

$-3.9m | $-5.6m

Net Income

$-3.7m | $-4.0m

Free Cash Flow

$-2.7m

Growth (TTM | estimate)

Revenue

5.7% | 10.2%

EBITDA

- | -

EBIT

20.4% | -60.3%

Net Income

18.1% | -1.5%

Free Cash Flow

36.2%

EPS

$-2.4

FCF per Share

$-1.7

Short interest

0.2%

Employees

Rev per Employee

$1.3m

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Get Started for Free Today

Xenetic Biosciences, Inc. Stock Analysis

Unlock Scores for Free

??

6 Analysts have issued a Xenetic Biosciences, Inc. forecast:

3x Hold

50%

3x Sell

50%

More details on Analyst Estimates Including Price Targets

6 Analysts have issued a Xenetic Biosciences, Inc. forecast:

Hold

50%

Sell

50%

Analyst Estimates with Stock Price Targets

Financial data from Xenetic Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	2.58 2.58	6% 6% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	3.24 3.24	7% 7% 126%
- Research and Development Expense	3.22 3.22	16% 16% 125%
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-3.88 -3.88	20% 20% -150%
Net Profit	-3.67 -3.67	18% 18% -142%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Xenetic Biosciences, Inc. Stock News

Neutral

Accesswire

●

12 days ago

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic Cancer

Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, PeriNess Company evaluating systemic recombinant human DNase I (DNase I) in combination with chemotherapy and immunotherapy platforms for the treatment of pancreatic carcinoma, colorectal cancer and other locally advanced or metastatic solid tumors FRAMINGHAM, MA / ACCES...

Neutral

Accesswire

●

2 months ago

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

Strategic focus on exploratory investigator-initiated clinical studies with institutional partners Continued progress of DNase I development program towards IND and first-in-human study for treatment of pancreatic carcinoma Ended the quarter with $5.2 million of cash to fund operations FRAMINGHAM, MA / ACCESS Newswire / May 14, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the...

Neutral

Accesswire

●

3 months ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

- Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting - Watch the "What This Means" video here FRAMINGHAM, MA / ACCESS Newswire / April 9, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or th...

More Xenetic Biosciences, Inc. News

Company Profile

Xenetic Biosciences, Inc. engages in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient's malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.

Head office	United States
CEO	James Parslow
Employees	2
Founded	2011
Website	www.xeneticbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now